Argenx Se (ARGX) Liabilities and Shareholders Equity (2015 - 2026)

Argenx Se (ARGX) posted quarterly Liabilities and Shareholders Equity of $10.0 billion for Q2 2026, up 39.81% year-on-year from $7.2 billion in Q2 2025, and up 15.54% on a QoQ basis from $8.7 billion in Q4 2025.

Argenx Se (ARGX) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends

Argenx Se (ARGX) has reported Liabilities and Shareholders Equity for 12 consecutive years, with $10.0 billion the latest figure, recorded in Q2 2026.

  • Quarterly Liabilities and Shareholders Equity rose 39.81% year-over-year to $10.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $18.7 billion (up 39.89% YoY) and the FY2025 annual result came in at $8.7 billion, up 39.99% from the prior year.
  • Liabilities and Shareholders Equity improved to $10.0 billion in Q2 2026 per ARGX's latest filing, from $8.7 billion in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for ARGX reached as high as $10.0 billion in Q2 2026 and fell as low as $3.1 billion in Q4 2022.
  • A 5-year average of $5.7 billion and a median of $4.8 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity slipped 1.71% — and 2024, when it soared 50.18%.
  • Year by year, Liabilities and Shareholders Equity stood at $3.1 billion in 2022, then surged by 44.93% to $4.5 billion in 2023, then soared by 36.55% to $6.2 billion in 2024, then surged by 39.99% to $8.7 billion in 2025, then climbed by 15.54% to $10.0 billion in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $10.0 billion, $8.7 billion, and $7.2 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn 5.13 Bn

Historic Data

Download Data
DateValue
Jun 30, 2026 10.03 Bn
Dec 31, 2025 8.68 Bn
Jun 30, 2025 7.18 Bn
Dec 31, 2024 6.20 Bn
Jun 30, 2024 4.80 Bn
Dec 31, 2023 4.54 Bn
Jun 30, 2023 3.19 Bn
Dec 31, 2022 3.13 Bn
Jun 30, 2022 3.25 Bn
Dec 31, 2021 2.85 Bn
Jun 30, 2021 3.21 Bn
Dec 31, 2020 2.11 Bn
Jun 30, 2020 2.30 Bn
Dec 31, 2019 1.63 Bn
Jun 30, 2019 1.15 Bn
Dec 31, 2018 658.26 Mn
Jun 30, 2018 519.58 Mn
Dec 31, 2017 535.30 Mn
Jun 30, 2017 267.70 Mn
Dec 31, 2016 152.65 Mn